NCT01602874撤回3 期
Multicenter, Randomized, And Double-Blind Study To Evaluate The Safety Of Tigecycline Versus A Ceftriaxone Regimen In The Treatment Of Complicated Intra-Abdominal Infections And Community-Acquired Pneumonia In Subjects Of 8-17 Years
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- Pfizer
- 主要终点
- Clinical efficacy response (cure, failure, or indeterminate) at the test of cure (TOC) visit for 2 co-primary populations: the clinically evaluable (CE) and clinical modified Intent-to-Treat (c-mITT) populations
研究概览
简要总结
The main purpose of this study is to compare the safety of tigecycline versus a ceftriaxone regimen in pediatric subjects (aged 8 to 17 years) with complicated intra-abdominal infections (cIAI) and community acquired pneumonia (CAP).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 8 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects 8 to 17 years old. Children with bone maturation less than 8 years old should be enrolled with caution due to potential risk of tooth discoloration.
- •Have a diagnosis of a serious infection (complicated intra-abdominal infections [cIAI] or community acquired pneumonia [CAP] as applicable) requiring hospitalization and administration of IV antibiotic therapy.
- •Criteria related indication (cIAI or CAP - as applicable), e.g., sign of systemic infection, signs and symptom.
排除标准
- •Subject with any concomitant illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and/or completion of the study, or could preclude the evaluation of the subject's response (e.g., life expectancy <30 days).
研究组 & 干预措施
A. Tigecycline
Experimental
干预措施: Tigecycline (Drug)
结局指标
主要结局
Clinical efficacy response (cure, failure, or indeterminate) at the test of cure (TOC) visit for 2 co-primary populations: the clinically evaluable (CE) and clinical modified Intent-to-Treat (c-mITT) populations
时间窗: 2 to 7 weeks for cIAI and 2 to 5 weeks for CAP
次要结局
- Clinical response at the IV last day of therapy (LDOT) for co-primary populations: the CE and c-mITT populations(5 days to 4 weeks for cIAI and 5 days to 2 weeks for CAP)
- Clinical response at follow up (FUP) visits for co-primary populations: the CE and c-mITT populations(5 to 9 weeks for cIAI and 5 to 7 weeks for CAP)
- Microbiological response at the subject and the pathogen level(5 to 9 weeks for cIAI and 5 to 7 weeks for CAP)
- Response rate by pathogen and minimum inhibitory concentration (MIC) value(5 to 9 weeks for cIAI and 5 to 7 weeks for CAP)
- Response rates for polymicrobial/monomicrobial infections, and susceptibility evaluations(5 to 9 weeks for cIAI and 5 to 7 weeks for CAP)
研究者
相似试验
撤回
3 期
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired PneumoniaCommunity Acquired Bacterial PneumoniaComplicated Intra-Abdominal InfectionNCT00914888Wyeth is now a wholly owned subsidiary of Pfizer
已完成
4 期
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)Intra-Abdominal InfectionDiverticulitisIntra-Abdominal AbscessCholecystitisAppendicitisPeritonitisNCT00230971Wyeth is now a wholly owned subsidiary of Pfizer473
撤回
3 期
Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric SubjectsSkin DiseasesInfectionNCT00911573Wyeth is now a wholly owned subsidiary of Pfizer
终止
2 期
Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired PneumoniaPneumonia, BacterialNCT00707239Pfizer108
已完成
4 期
Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin InfectionsSkin Diseases, BacterialNCT00368537Wyeth is now a wholly owned subsidiary of Pfizer550